治疗淋巴肿瘤患者后出现临床无明显表现的克隆细胞遗传学异常。

Clinically silent clonal cytogenetic abnormalities arising in patients treated for lymphoid neoplasms.

机构信息

Department of Hematopathology, UT MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Leuk Res. 2014 Aug;38(8):896-900. doi: 10.1016/j.leukres.2014.05.015. Epub 2014 Jun 4.

DOI:10.1016/j.leukres.2014.05.015

Abstract

Newly emerged clonal cytogenetic abnormalities (CCA) in patients with prior cytotoxic therapy are highly concerning for therapy-related myeloid neoplasms (t-MN). In some patients, however, CCA appeared to be clinically "silent". In this study, we describe 25 patients who developed CCA after they received cytotoxic therapies for lymphoid neoplasms but never developed t-MN. These clinically "silent" CCA were always present as single abnormalities, often detected in a small subset of cells, and tended to disappear over time. We conclude that the occurrence of CCA is not always associated with t-MN. Clinical correlation is essential to guide a proper management of these patients.

摘要

新出现的克隆细胞遗传学异常（CCA）在先前接受细胞毒性治疗的患者中高度提示治疗相关髓系肿瘤（t-MN）。然而，在某些患者中，CCA 似乎在临床上“沉默”。在这项研究中，我们描述了 25 例患者，他们在接受用于治疗淋巴肿瘤的细胞毒性治疗后出现了 CCA，但从未发生 t-MN。这些临床上“沉默”的 CCA 始终表现为单一异常，通常在一小部分细胞中检测到，并且随着时间的推移趋于消失。我们得出结论，CCA 的发生并不总是与 t-MN 相关。临床相关性对于指导这些患者的适当治疗至关重要。